Kopran Ltd
As of 20 Nov 2026, Kopran is in Stage 2, the uptrend phase, now in week 24 (since 1 Jun 2026). It closed at ₹263, 9.5% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More about the company
Pro read
ProKOPRAN is about 6 months into its Stage 2 advance, 0% below its 50-day average and 10% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.
Its relative strength is 94 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Stocks with a similar setup ran 0.1 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 17% above entry.
The trend read holds while it stays in Stage 2. A close below ₹264, its 50-day average, would put it at rest; ₹233, 20% under its 52-week high of ₹291, is where a trailing stop would sit.
Setup-score rank among Stage 2 peers: #20 of 50 in Pharmaceuticals · #27 of 61 in Health Care
Is KOPRAN early, or has it already run? Pro answers that for every NSE stock, after every close.
KOPRAN among Pharmaceuticals18th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …18 | KOPRAN | Stage 2 · wk 24 | 94 | −0.3% |
Mutual fund holdings
Held by 1 mutual funds in portfolios to October 2026: 0 active funds and 1 index funds and ETFs.
In October, no active fund changed its holding.
All 1 funds and what each did in October
Mutual funds holding KOPRAN: the ten largest and the month’s moves →
Kopran: quick answers
What stage is Kopran in?
As of 20 Nov 2026, Kopran (KOPRAN) is in Stage 2, the uptrend phase. It entered Stage 2 on 1 Jun 2026 and is in week 24. What the four stages mean
Is Kopran in an uptrend?
Yes. Kopran is in a Stage 2 uptrend. It trades 37.6% above its 200-day average, which is rising.
How far is Kopran from its 52-week high?
Kopran closed at ₹263 on 20 Nov 2026, 9.5% below its 52-week high of ₹291. Its 52-week low is ₹108.
How has Kopran performed over the past year?
As of 20 Nov 2026, Kopran is up 83.8% over the past year and up 74.9% so far in 2026.
Which sector and industry is Kopran in?
Kopran is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company offers drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.